In Brief: LaserSight Inc.
This article was originally published in The Gray Sheet
Executive Summary
LaserSight Inc.: Commences Phase IIb U.S. clinical trials of its PhotoScan 2000 excimer laser for photorefractive keratectomy (PRK). The 125-patient, five-site study includes patients with up to -10 diopters of nearsightedness, LaserSight says. Phase III trials of the PRK device are ongoing in Canada and Europe. The firm also is conducting Phase II trials in the U.S., Canada and Europe for photoastigmatic refractive keratectomy (PARK), designed to correct "myopic astigmatism up to 6.5 diopters in conjunction with the correction of myopia of up to -10.5 diopters"...